Celularity Inc(CELU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 6:09 PM ET (Korea 11/7 08:09)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | 61.93% | Shs Outstand | 29.3M | Perf Week | -5% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 12.4M | Perf Month | -47.94% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 6.79% | Short Float | 3.57% | Perf Quarter | 10.7% |
| Income | -0.05B | P/S | 1.32 | EPS this Y | - | Inst Trans | -0.02% | Short Ratio | 0.11 | Perf Half Y | -13.62% |
| Sales | 0.02B | P/B | - | EPS next 5Y | - | ROA | -42.7% | Short Interest | 0.44M | Perf YTD | -31.52% |
| Book/sh | -1.21 | P/C | 41.81 | EPS past 3/5Y | - 49.85% | ROE | - | 52W High | -70.19% ($2.55) | Perf Year | -55.02% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | 13.88% 13.21% | ROIC | -218.95% | 52W Low | 35.71% ($0.56) | Perf 3Y | -64.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 47.25% | Gross Margin | -17% | Volatility(W/M) | 10.07% 14.85% | Perf 5Y | -98.96% |
| Dividend TTM | - | EV/Sales | 5.03 | Sales Y/Y TTM | -58.14% | Oper. Margin | -264.26% | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.1 | EPS Q/Q | 101.82% | Profit Margin | -248.05% | RSI (14) | 35.97 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.11 | Sales Q/Q | -5.3% | SMA20 | -25.08% ($1.01) | Beta | 0.89 | Target Price | $6 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -41.04% ($1.29) | Rel Volume | 0.02 | Prev Close | $0.73 |
| Employees | 115 | LT Debt/Eq | - | EPS/Sales Surpr. | -36% - | SMA200 | -29.18% ($1.07) | Avg Volume(3M) | 3.87M | Price | $0.76 |
| IPO | 2019/8/8 | Option/Short | Yes/Yes | Trades | 258 | Volume | 60,569 | Change | 4.8% |
🧬 This regenerative medicine company treats diabetic foot ulcers and tendon injuries using cells and biomaterials extracted from post-birth placentas. Building on revenue from its biobanking (umbilical cord storage) business, the company is working toward commercializing FDA 510(k)-cleared medical devices, including tendon lab products and bone fillers.
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded less than usual. That is 2% of its average volume.
CELU has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $132. Peers typically go for $917.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #457 of 597 in the industry
Based on market cap of $25M.
RNAZ#455 TransCode Therapeutics Inc $25M PER - 
EVAX#456 Evaxion A/S ADR $25M PER - CELU#457 Celularity Inc $25M PER - 
IMMP#458 Immutep Limited ADR $25M PER - 
NXTC#459 Nextcure Inc $24M PER - 
FAQ
What kind of company is CELU?
CELU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CELU?
The market cap of CELU is approximately $25M, ranking 5,124 within its sector.
What is the 52-week high and low for CELU?
CELU has recorded a 52-week high of $2.55 and a low of $0.56.
